Education
About Us
Working with TipRanks
Follow Us
Septerna, Inc. (SEPN)
NASDAQ:SEPN
SEPN Stock Chart & Stats
$26.73
$0.38(1.86%)
At close: 4:00 PM EST
$26.73
$0.38(1.86%)
Day’s Range― - ―
52-Week Range$4.17 - $30.50
Previous CloseN/A
Volume49.14K
Average Volume (3M)273.14K
Market Cap
$1.20B
Enterprise Value$407.54M
Total Cash (Recent Filing)$474.35M
Total Debt (Recent Filing)$24.11M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Mar 26, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding44,774,193
10 Day Avg. Volume298,641
30 Day Avg. Volume273,139
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)210.70
P/FCF Ratio-3.26
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue18.49
Enterprise Value/Gross Profit18.49
Enterprise Value/Ebitda-4.64
Forecast
1Y Price Target
$33.14Price Target Upside23.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$85.24M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSelection of SEP-479 as the next-generation oral PTH1R agonist with a Phase 1 start planned in the first half of 2026 creates a clear clinical milestone that can drive investor interest.
Commercial DifferentiationSEP-479's potential to be the first oral therapy for hypoparathyroidism in a market dominated by injectables offers a meaningful commercial advantage if approvals are achieved.
Partnership And FundingThe collaboration with Novo Nordisk validates the GPCR Native Complex platform and provides funding support that extends the company's cash runway into 2029 while lowering near-term R&D spend.
Bears Say
Clinical Efficacy UncertaintyEarly-stage status of SEP-631 and SEP-479 means initial human trials must demonstrate clear efficacy and tolerability before commercial potential becomes realistic.
Competition And Financing RiskStrong competition from established injectable therapies and the possibility of missed milestones or funding shortfalls could pressure valuation if commercialization or partnership payments do not materialize.
Safety And Regulatory RiskClinical programs face safety and regulatory hurdles that could delay development timelines or prevent approvals for SEP-479 or SEP-631.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $4.17 and its highest was $30.50 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.20B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 69 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Nov 19, 2025. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.057.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,774,193 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of $0.18 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went up 6.501%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.14 (23.98% Upside)
$33.14 (23.98% Upside)
Blogger Sentiment
Bullish
SEPN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 239.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.60%
12-Months-Change
Fundamentals
Return on Equity
-22.38%
Trailing 12-Months
Asset Growth
248.09%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$33.14
▲(23.98% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Day One Biopharmaceuticals
―
Ownership Overview
Currently, No data available
---